RYTM PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

RYTM ▼ -1.08% at T+5d

LONG call ✗ call lost -1.08% · α vs SPY -3.07% · entry $92.31 → $91.31

Next anchor: T+20d in 14d

Currently $90.64 · -1.81% from $92.31 entry

Entry anchored
May 5, 2026
via day open

T+1d

+4.66%

call +4.66% · α +3.27%

$96.61

settled 14d ago

T+5d

-1.08%

call -1.08% · α -3.07%

$91.31

settled 8d ago

T+20d

—

call — · α —

—

in 14d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS loss of -$0.73, beating the -$0.86 estimate by 15.2%. The beat was driven by strong IMCIVREE sales, including the newly approved acquired hypothalamic obesity indication, but the company's net loss widened to -$56.7M from -$50.8M a year ago, and operating expenses surged 41% YoY.

Actionable Insight

The strong Q1 beat and rapid early adoption of IMCIVREE in acquired HO (150+ patient start forms in 6 weeks) signal accelerating commercial traction. Watch for upcoming catalysts: Phase 2 PWS data (Q2 2026), RM-718 data (mid-2026), and Japan PMDA decision (H2 2026). The stock has historically underperformed post-earnings (avg T+20 -5.82% on prior reports), but this beat is more substantive than prior neutral filings.

Key Facts

Q1 2026 revenue $60.1M vs consensus $56.1M (beat)
Q1 2026 EPS -$0.73 vs consensus -$0.86 (15.2% beat)
IMCIVREE approved by FDA for acquired hypothalamic obesity on March 19, 2026; >150 patient start forms received in first 6 weeks
European Commission granted Marketing Authorization for IMCIVREE in acquired HO on May 1, 2026
Net loss widened to -$56.7M from -$50.8M YoY; operating expenses rose to $112.5M from $79.7M
Cash position $340.6M as of March 31, 2026; company expects sufficient runway for at least 24 months
Non-GAAP operating expense guidance for FY2026: $385M-$415M

Financial Impact

Revenue beat of $4.0M (7.1%) vs consensus; EPS beat of $0.13 (15.2%) vs consensus; net loss widened by $5.9M YoY

revenueepsnet lossoperating expenses

Risk Factors

Operating expenses growing faster than revenue (41% YoY vs 59% revenue growth)
EMANATE Phase 3 trial missed primary endpoint in March 2026, creating pipeline uncertainty
Sequential U.S. revenue declined 5% QoQ due to inventory and insurance transitions
High cash burn rate ($48.3M in Q1 2026) despite $340.6M cash position

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

91% bullish (22 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3287506

7 reports for RYTM

T+1T+5T+20T+60

33% Hit rate 1 of 3 directional calls best @ T+5▲ +15.11%May 1, 2026

Filters

Reports for RYTM — sortable, filterable
	Type				Now
May 12, 2026 8d ago	Press Release NEUTRAL ★ 4/10	$91.31 $86.84	▼ −4.90%	▼ −4.97%	$90.64 (−0.73%)
May 5, 2026 15d ago	8-K MIXED ★ 6/10	$92.31 $91.31	▼ −1.08%	▼ −3.07%	$90.64 (−1.81%)
May 5, 2026 15d ago	Press Release BULLISH ★ 7/10	$92.31 $91.31	▼ −1.08%	▼ −3.07%	$90.64 (−1.81%)
May 1, 2026 19d ago	Press Release BULLISH ★ 7/10	$81.81 $94.17	▲ +15.11%	▲ +12.76%	$90.64 (+10.79%)
Apr 3, 2026 6w ago	8-K NEUTRAL ★ 3/10	$86.96 $86.81	▼ −0.17%	▼ −4.31%	$90.64 (+4.23%)
Mar 1, 2026 11w ago	Press Release BULLISH ★ 8/10	$94.94 $93.00	▼ −2.04%	▼ −0.84%	$90.64 (−4.53%)
Feb 26, 2026 11w ago	8-K BULLISH ★ 8/10	$98.07 $91.46	▼ −6.74%	▼ −5.61%	$90.64 (−7.58%)

US Market Status

Market Closed — Opens Thu (< 1m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access